Published • loading... • Updated
Vertex Has a Head Start in Non-Opioid Pain. Eli Lilly Just Spent Billions to Catch Up. Here's What That Means for Both Stocks.
Summary by The Motley Fool
1 Articles
1 Articles
Vertex Has a Head Start in Non-Opioid Pain. Eli Lilly Just Spent Billions to Catch Up. Here's What That Means for Both Stocks.
Key PointsVertex Pharmaceuticals and Eli Lilly are both going after the non-opioid pain management market.Vertex Pharmaceuticals has a lead, but both drugmakers could be successful in this niche.There are good reasons to invest in either stock. 10 stocks we like better than Vertex Pharmaceuticals › Vertex Pharmaceuticals (NASDAQ: VRTX) and Eli Lilly (NYSE: LLY) are two leading drugmakers that dominate their respective core therapeutic areas. Ver…
·Alexandria, United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left1Leaning Right0Center0Last UpdatedBias Distribution100% Left
Bias Distribution
- 100% of the sources lean Left
100% Left
L 100%
Factuality
To view factuality data please Upgrade to Premium
